Transcriptomic signatures of tumors undergoing T cell attack.
Aishwarya GokuldassAimilia SchinaMartin LaussKatja HarbstChristopher Aled ChamberlainArianna DraghiMarie Christine Wulff WestergaardMorten NielsenKrisztian PappZsofia SztupinszkiIstvan CsabaiInge Marie SvaneZoltan SzallasiGöran JönssonMarco DoniaPublished in: Cancer immunology, immunotherapy : CII (2021)
The TuTack scores measure the effects on tumor cells of an anti-tumor immune response and represent a comprehensive method to identify immunologically responsive tumors. Our findings suggest that TuTack may allow patient selection in immunotherapy clinical trials and warrant its application in multimodal biomarker strategies.